Mediterranean diet and brain structure in a multiethnic elderly cohort
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 27, 2015
- Accepted in final form July 16, 2015
- First Published October 21, 2015.
Article Versions
- Previous version (October 21, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Yian Gu, PhD,
- Adam M. Brickman, PhD,
- Yaakov Stern, PhD,
- Christian G. Habeck, PhD,
- Qolamreza R. Razlighi, PhD,
- José A. Luchsinger, PhD,
- Jennifer J. Manly, PhD,
- Nicole Schupf, PhD,
- Richard Mayeux, MD and
- Nikolaos Scarmeas, MD
- Yian Gu, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Adam M. Brickman, PhD,
Currently serve on the scientific advisory board of Keystone Heart and ProPhase.
NONE
NONE
Editorial board member of The Journal of the International Neuropsychological Society. Editorial board member of Neuropsychology Review
NONE
NONE
NONE
Consultant for ProPhase. Years: 2007-2011 and 2013-present. Consultant for Keystone Heart. Years: 2012-Present.
NONE
NONE
NONE
NONE
grant support: NIH AG029949 PI 2007-2012 NIH AG024708 PI 2004-2006 NIH AG034189 PI 2010-2015 NIH AG043337 PI 2012-2014
grant support: Columbia University PI 2008-2009 Columbia University PI 2012-2013
grant support: Alzheimer's Association PI 2005-2007 Alzheimer's Association PI 2010-2012 Mary E. Groff Surgical Medical Research and Education Charitable Trust PI 2012-2013
NONE
NONE
NONE
NONE
NONE
NONE
- Yaakov Stern, PhD,
Delirium Program Project Scientific Advisory Board
NONE
2012: (1) Toronto, Canada, Rotman Institute, Annual Baycrest Research Division Conference, Reimbursement;(2) Newark, NJ, Janssen, LLC and Pfizer Alzheimer's Disease Progression Monitoring Advisory Board Meeting, Honorarium; (3) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (4) Boston, Janssen, Global Advisory Committee Meeting for INROADS study, Reimbursement and Honorarium; (5) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; 2013: (6) Nashville, TN, ADCS, Advisory Board Meeting, Reimbursement; (7) , Hawaii, INS, Annual INS Mtg, Honorarium; (8) Florence, Italy, Accera, Inc./NYU,AD PD meeting, Reimbursement; (9) San Diego, CA,ADC, Directors' Meeting, Reimbursement; (10) (11) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (12) Chicago, AbbVie, Advisory Board Meeting, Honorarium; (13) Boston, MA, AAIC Annual Meeting, reimbursement; (14) Turin, Italy, Int'l Association of Logopedics and Phoniatrics, 29th World Congress of the IALP honorarium; (15) Toronto, Canada, MaRS Health and Digital Media Workshop, Reimbursement; (16) Chicago, Takeda Global Research & Development Center, Inc., Adjudication Kick-off Meeting, Honorarium; (17) Milan, Italy, UNIVERSIT? DEGLI STUDI DI MILANO, CATTEDRA DI NEUROLOGIA, 8th Conference of Neurology: Cognitive Reserve in Aging and Alzheimer's Disease, reimbursement; (18) Tel Aviv, Israel, University of Tel Aviv, Annual Brainstorming of AD, reimbursement; (19) Boston, MA, Eli Lilly, Measuring Function in Alzheimer?s Disease Working Group, Honorarium; 2014: (21) Chicago, Alzheimer's Association (MSAC), Advisory Board Meeting, Reimbursement; (22) Barcelona, Spain, International Debate on Ageing and mental health, reimbursement; (23) Chicago, AAAS, Symposium: The Science of Resilient Aging, reimbursement; (24) Washington, D.C., IOM, Workshop on Cognitive Aging, reimbursement; (25) Philadelphia, ADNI, Steering Committee Meeting, reimbursement; (26) Boston, MA, Delirium PPG SAB-Planning of 2014, Reimbursement; (27) Copenhagen, Denmark, AAIC Annual Meeting, AIC and Lilly Symposium, Honorarium;(28) Philadelphia, Eli Lilly, Honorarium; (29) Boston, Delta Quest Foundation, Honorarium; 2015, (30) Dallas, TX, Eli Lilly, Working Group Mtg, Honorarium (31) Dallas, TX, Eli Lilly Primary Outcome Mtg, Honorarium;
1) Journal of the International Neuropsychological Society, Associate Editor, 1999-2013, Editorial Board 2013- present, 2)Cognitive and Behavioral Neurology, Editorial Board, 2005-present, 3)Neuropsychology, Editorial Board, 2006-present
NONE
NONE
NONE
(1) Allergan, (2) Cephalon, (3) Elan, (4) Eisai, (5) Pfizer, (6) Ortho-McNeil Neurologics, (7) Merck &Co, (8) Glaxo Smith Kline, (9) Ely Lily, (10) Janssen Alzheimer Immunotherapy (11) AbbVie Inc. (12) Takeda Global Research & Development Center Inc. (13) Piramal Imaging SA
NONE
NONE
NONE
(1) Piramal, (2) Forest Pharmeceutical
(1) NIH/NIA, R01AG034178, PI, 2009-2014. (2) NIH/NIA, 5R01AG007370-24, PI, 1989-2011. (3) NIH/NIA, (4) NIH/NIA, R01AG037212-05, Co-I, 2010-2015. (5) NIH/NIA, P50 AG08702- 25, Co-I, 1997-2015. (6) NIH/NIA, R01AG038465-04, PI, 2011- 2016. (7) NIH/NIA, R01AG033546-05, PI 2010-2015. (8) NIH/NIA, R01AG026158-09, PI, 2004-2016. (9) NIH/NINDS, R01NS070600-03, Co-I, 2010-2015. (10) NIH/NIA, R37NS029993- 21, Co-I, 2013-2015. (11) NIH, R01AG036469-03, Co-I, 2011- 16. (12) NIH, R01AG041795-01A1, Co-I, 2013-2018. (13) NIA, R01AG043463, Co-I, 2012-2017.
NONE
1) Alzheimer's Drug Development Foundation
NONE
(1) The Dependence Scale measures is licensed for use by commercial entities by Columbia University, and I receive funds from these licenses.
NONE
NONE
NONE
NONE
- Christian G. Habeck, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
R01AG038465 Stern (PI) 09/01/11 ? 08/31/16 Exploring Cognitive Aging Ability Using Reference Ability Networks The proposed research program constitutes a major reevaluation of the methods and goals of the study of cognitive aging that should provide major new, integrative, and perhaps simplifying, insights into the neural basis of the most important and central features of cognitive aging. Role: co-I R01AG033546 Stern (PI) 09/15/10 - 05/31/15 Exercise, aging, and cognition: Effect and mechanisms The goal of the proposed study is to extend the investigation of the beneficial effects of aerobic exercise to younger individuals, aged 25-40 and 50-65. Role: co-I R01 AG026158 Stern (PI) 09/15/04 - 08/31/16 Imaging of Cognition, Learning, and Memory in Aging This work will lead to better understanding of how aging and AD pathology impacts on the neural systems that mediate cognitive function and the neural mechanisms that differentiate successful and unsuccessful aging. In turn, it may provide clues for remediating or preventing age-related cognitive changes and delaying the onset of AD. Role: co-I R01NS076837 Cosentino (PI) 09/21/12 - 07/31/17 Examination of the Earliest Symptoms and Biomarkers of FTLD MAPT Carriers This project examines the earliest clinical symptoms of FTLD in carriers of a tau mutation. Role: co-I R01MH101172 Posner (PI) 09/01/11 ? 08/31/16 Imaging Stimulant Effects on Emotional Liability in Children with ADHD Role: co-I R21MH099388 Steinglass (PI) 01/13/14 ? 12/31/15 Multimodal imaging of the Mesocortical system in anorexia nervosa This project will use complementary neuroimaging techniques to study neural circuitry in anorexia nervosa. Using resting state functional neuroimaging, diffusion tensor imaging, and arterial spin labeling we will evaluate the mesocortical system in individuals with anorexia nervosa before and after weight restoration treatment, as compared with healthy controls. Role: co-I R01AG043463 Ochsner (PI) 09/01/12-8/31/17 Understanding cognitive mechanisms of emotion regulation in aging This project seeks to understand the ways in which the psychological and neural mechanisms underlying the cognitive regulation of emotion change in older adults. Role: co-I ADDF Gibson (PI) 01/01/15 ? 12/31/16 Benfortiamine in Alzheimer ?s Disease: A pilot Study This pilot study will test whether a vitamin B1 derivative that increases glucose utilization and diminishes AD symptoms in mouse models will be beneficial in patients with AD. Role: co-I R01AG043679 Gibson, Jordan (co-PIs) 09/01/14-05/31/19 Benfortiamine in Alzheimer ?s Disease: A pilot Study This pilot study will test whether a vitamin B1 derivative that increases glucose utilization and diminishes AD symptoms in mouse models will be beneficial in patients with AD. Role: co-I
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Qolamreza R. Razlighi, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- José A. Luchsinger, PhD,
(1)Commercial: Nutricia, Inc
NONE
NONE
Alzheimer's disease and associated disorders, editor in chief, 2015-Journal of Alzheimer's Disease, associate editor, 2008-
NONE
Biessels GJ, Luchsinger JA. Diabetes and the Brain. Humana, Press 2009. Received $509.78 on 04/28/2010
NONE
NONE
NONE
NONE
NONE
NONE
Agency: PCORI (Easygrant ID 7160) (J. Luchsinger), Title: Northern Manhattan Hispanic Caregiver intervention Effectiveness Study (NHiCE), Dates: 12/01/2013-11/30/2016, Goals: to compare the effectiveness of 2 dementia caregiver interventions, the New York University Caregiver Intervention, and the translation of the Resources for Enhancing Caregiver?s Health (REACH OUT) in a pragmatic randomized trial of 200 Hispanic relative caregivers of persons with dementia. Role: PI, Agency: NINR (1R01NR014430-01), Title: New York City Hispanic Dementia Caregiver Research Program (NHiRP), Principal investigator: Lucero; Luchsinger (contact); Mittelman, Dates: 06/01/13-05/31/18 Goals: to establish a program of research about Hispanic caregivers of persons with dementia. NHiRP will provide long term follow-up to an existing clinical trial, create a registry of caregivers, and develop an internet based intervention working with caregivers. Responsibilities: PI, Agency: NIDDK, Title: Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE; 1U01DK098246). Principal Investigator: D. Nathan, J. Lachin, Dates: 12/01/12-07/31/20, Goals: GRADE is a multi-center randomized clinical trial to evaluate the relative long-term metabolic and clinical effects of four classes of drugs in combination with metformin for the treatment of type 2 diabetes. Responsibilities: PI of Cognitive Coordinating Center. Agency: NIMHD (P60 MD00206), Title: Northern Manhattan Center of Excellence in Minority Health and Health Disparities (NOCEMHD). Principal investigator: J. Luchsinger, Dates: 05/01/09-01/31/15, Goals: this center grant has 3 projects related to minority health including a prospective study of cognition in persons with diabetes, and 2 trials of community participatory research in diabetes and hypertension. Responsibilities: Center director, Agency: NIDDK (2U01DK048404), Title: DPPOS Neurocognitive Reading Center Principal Investigator: J. Luchsinger, Dates: 07/01/09-01/31/15, Goals: Coordinate the administration of neurocognitive assessments in the 26 sites of the Diabetes Prevention Program Outcomes Study (DPPOS) including traning and quality control. This grant is a subcontract to the St. Luke?s Roosevelt Hospital Center DPPOS site (PI: X. P-Sunyer). Responsibilities: principal investigator. Agency: NIMHD (3P60MD000206-09S2), Title: Bioethics in the Northern Manhattan Center of Excellence in Minority Health and Health Disparities (NOCEMHD) Principal investigator: J. Luchsinger. Dates: 09/22/2011-01/31/15, Goals: The goal is to conduct a 1-year bioethics program to address unresolved bioethics issue in minority health research. Responsibilities: principal investigator, Agency: NIMHD (3P60MD000206-09S1), Title: Environmental health disparities in NOCEMHD, Dates: 09/22/2011-01/31/2015 Principal investigator: J. Luchsinger. Goals: This application established the Contextual Health Disparities-Core (COHD) in the Northern Manhattan Center of Excellence in Minority Health and Health Disparities at Columbia University (NOCEMHD) Responsibilities: principal investigator. Agency: NIA (1R01AG037212-01), Title: Epidemiology of Biomarkers of Risk and Progression in Late Onset Alzheimer's Disease. Dates: 04/01/10-03/31/15, Principal Investigator: R. Mayeux, N.Schupf. Goals: To investigate biomarkers that predict Alzheimer?s disease risk. Responsibilities: co-investigator. Agency: NIA (R01AG034189), Title: White Matter Hyperintensities in aging and dementia. Dates: 3/15/10-2/28/15), Principal investigator: A. Brickman. Goals: to investigate the role of white matter hyperintensities ascertained on MRI in cognitive aging. Responsibilities: co-investigator. Agency: NIMH (R01 MH104574-01). Title: Peer-led healthy lifestyle program in supportive housing, Dates: 7/14/14-06/13/19. Principal Investigator: L. Cabassa. Goals: to carry out a clinical trial of a weight loss intervention among persons with severe mental illness. Responsibilities: co-investigator
NONE
Institute for the Study of Aging:
NONE
NONE
NONE
NONE
NONE
NONE
- Jennifer J. Manly, PhD,
Reimbursement of travel costs associated with serving on the Medical and Scientific Advisory Board of the Alzheimer's Association
NONE
Travel costs as a speaker at AAIC, Vancouver 2012, Alzheimer's Association (non-profit)
Journal of the International Neuropsychological Society, associate editor, 2005 - 2014
NONE
NONE
NONE
National Academies of Medicine - 2014
NONE
NONE
NONE
NONE
1) National Institute on Aging, R01 AG028786, Role: Principal Investigator, 09/15/07 ? 06/30/13 (NCE) 2) National Institute on Aging, R01 AG037212, Role: Co-Investigator, 05/01/10 - 04/30/15
NONE
2) Alzheimer?s Association, IIRG-11-202789, Role: Principal Investigator, 08/15/11 ? 08/14/14
NONE
NONE
NONE
NONE
NONE
NONE
- Nicole Schupf, PhD,
NONE
NONE
New York Methodist Hospital, Honorarium
NONE
NONE
NONE
NONE
Janssen Alzheimer Immunology R&D LLC
NONE
AAIC: Down syndrome Professional Interest Group Executive Committee
NONE
NONE
support from NIH #P01HD035897(Co-I), (2010 - 2015) NIH #R01AG037212 (Co-PI), (2010-2015) NIH #U01 AG023749 (Co-PI),(2014 - 2019) NIH #P50 AG08702 (Co-I), (2010-2015) NIH #R01AG036040 (Co-I), (2009-2014) NIH #AG034189 (Co-I) (2010-2015) NIH #R01 DE022658 (Co-I) (2013-2016) ADDF (Co-I) ( 2015-2016) NIH R01 AGO43679 (2014-2019)
NYS Institute for Basic Research in Developmental Disabilities
Alzheimer Association IIRG-11-20279 (Co-I) 2012-2015
NONE
NONE
NONE
NONE
NONE
NONE
- Richard Mayeux, MD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
RO1 AG037212 Epidemiology of Biomarkers of Risk and Progression in Late onset Alzheimer?s Disease. Principal Investigator
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nikolaos Scarmeas, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Federal NIA grant AG028506
NONE
Alzheimer?s Association grant IIRG-04-1353
NONE
NONE
NONE
NONE
NONE
NONE
- From The Taub Institute for Research in Alzheimer's Disease and the Aging Brain (Y.G., A.M.B., Y.S., C.G.H., O.R.R., J.A.L., J.J.M., N. Schupf, R.M., N. Scarmeas), The Gertrude H. Sergievsky Center (A.M.B., Y.S., C.G.H., J.A.L., J.J.M., N. Schupf, R.M., N. Scarmeas), the Department of Neurology (Y.G., A.M.B., Y.S., C.G.H., J.J.M., R.M.), the Department of Medicine (J.A.L.), and the Division of Epidemiology, Joseph P. Mailman School of Public Health (J.A.L., N. Schupf), Columbia University, New York, NY; and the National and Kapodistrian University of Athens Medical School (N. Scarmeas), Greece.
- Correspondence to Dr. Gu: yg2121{at}columbia.edu
Article usage
Cited By...
Letters: Rapid online correspondence
- Mediterranean diet and therapeutic implications.
- Rajiv Kumar, Professor, Dept of Pharmacology, Goverment Medical College & Hospital, Chandigarh, India.DRrajiv.08@gmail.com
Submitted December 01, 2015
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan